This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Crispr Therapeutics Ag. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations of Lalit Kumar in Antibody Development
Introduction
Lalit Kumar is an accomplished inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of high-affinity antibodies.
Latest Patents
Lalit Kumar holds a patent for "Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor." This patent describes high-affinity antibodies capable of binding to a single-chain variable fragment (scFv) of the anti-CD70 antibody. These antibodies are designed to be expressed on the cell surface as part of a chimeric antigen receptor (CAR). The patent also outlines methods for producing such anti-scFv antibodies and their applications in detecting T cells that express an anti-CD70 CAR.
Career Highlights
Lalit Kumar is currently associated with Crispr Therapeutics AG, where he continues to work on innovative solutions in the field of gene editing and antibody development. His expertise in antibody engineering has positioned him as a valuable asset in the biotechnology sector.
Collaborations
Lalit collaborates with Mary-Lee Dequeant, contributing to advancements in their shared field of research.
Conclusion
Lalit Kumar's work in developing anti-idiotype antibodies represents a significant advancement in biotechnology. His contributions are paving the way for new therapeutic approaches in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile